• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by DexCom Inc.

    4/15/26 4:13:39 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care
    Get the next $DXCM alert in real time by email
    DEFA14A 1 dxcm-defa14a2026xnaa.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a)
    of the Securities Exchange Act of 1934
    (Amendment No. )

    Filed by the Registrant  ý
    Filed by a party other than the Registrant  ☐

    Check the appropriate box:
    ☐
    Preliminary Proxy Statement
    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐
    Definitive Proxy Statement
    ý
    Definitive Additional Materials
    ☐
    Soliciting Material under §240.14a-12
    dexcom-logoxgreenxrgb.jpg
    DexCom, Inc.
    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):
    ý
    No fee required
    ☐
    Fee paid previously with preliminary materials
    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11




    dxcm-naa_page1.jpg



    dxcm-naa_page2.jpg

    Get the next $DXCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DXCM

    DatePrice TargetRatingAnalyst
    5/12/2026$77.00Buy
    The Benchmark Company
    3/24/2026$90.00In-line → Outperform
    Evercore ISI
    1/12/2026$71.00Equal Weight → Underweight
    Barclays
    12/2/2025$75.00Equal-Weight → Overweight
    Morgan Stanley
    11/25/2025$68.00In-line
    Evercore ISI
    10/21/2025$85.00Buy
    Stifel
    9/8/2025Outperform → Perform
    Oppenheimer
    8/21/2025$100.00Buy
    Argus
    More analyst ratings

    $DXCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience

    Company establishes permanent council to drive ongoing innovation guided by community feedback Report outlines targeted commitments Dexcom is making to address sentiments shared by council members Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, healthcare professionals and community leaders, along with clear, actionable company commitments to further elevate product performance and user experience. Building on its position as the manufacturer of the most accurate CGM systems1, Dexcom continues to listen, innovate and act on customer insights to strengthen its techno

    6/2/26 9:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users

    Through ongoing quality and accounting reviews, Dexcom discovered two lots of scrapped product were stolen by a third party before destruction and sold into the market. Dexcom is working closely with the FDA and other authorities to ensure patient safety and to investigate the crime. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties. Scrapping limited amounts of sensors that do not meet Dexcom standards is a routine

    5/26/26 9:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany

    Dexcom has announced a new continuous glucose monitoring system designed for people using basal insulin, oral therapies or GLP-1 receptor agonists1. The new system will be available shortly. Dexcom Flex provides real-time glucose data, personalised behavioural insights, and simplified tracking tools to support informed decision-making. DexCom, Inc. (NASDAQ:DXCM), a global leader in continuous glucose monitoring, today announced Dexcom Flex, a new CGM system designed specifically for adults with Type 2 diabetes who are not using intensive insulin therapy. The new system will be available in Germany soon. This press release features multimedia. View the full release here: https://www.

    5/18/26 7:31:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Altman Steven R was granted 5,565 shares (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    6/1/26 5:35:10 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    6/1/26 5:34:59 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    6/1/26 5:35:04 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Dexcom with a new price target

    The Benchmark Company initiated coverage of Dexcom with a rating of Buy and set a new price target of $77.00

    5/12/26 8:31:19 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Dexcom from In-line to Outperform and set a new price target of $90.00

    3/24/26 9:07:04 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom downgraded by Barclays with a new price target

    Barclays downgraded Dexcom from Equal Weight to Underweight and set a new price target of $71.00

    1/12/26 8:59:23 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    SEC Filings

    View All

    $DXCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    DexCom Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - DEXCOM INC (0001093557) (Filer)

    5/28/26 5:15:16 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by DexCom Inc.

    SD - DEXCOM INC (0001093557) (Filer)

    5/28/26 4:10:18 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by DexCom Inc.

    144 - DEXCOM INC (0001093557) (Subject)

    5/21/26 5:05:11 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/13/24 5:02:33 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/23 11:16:37 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/22 3:43:37 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Financials

    Live finance-specific insights

    View All

    Dexcom Reports First Quarter 2026 Financial Results

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended March 31, 2026. First Quarter 2026 Financial Highlights: Revenue grew 15% year-over-year to $1.192 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and international revenue grew 26% on a reported basis and 17% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $255.3 million or 21.4% of revenue, an increase of 850 basis points compared to the first quarter of 2025. Non-GAAP operating income* of $264.4 million or 22.2% of reported revenue, an increase of 840 basis points compared to the first quarter of 2025. F

    4/30/26 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time

    DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, April 30, 2026. Management will hold a conference call to review the company's first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the s

    4/2/26 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights: Revenue grew 13% year-over-year to $1.260 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and international revenue grew 18% on a reported basis and 15% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $323.0 million or 25.6% of revenue, an increase of 860 basis points compared to the fourth quarter of 2024. Non-GAAP operating income* of $331.5 million or 26.3% of reported revenue, an increase of 750 basis points compared to the fourth

    2/12/26 4:03:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Leadership Updates

    Live Leadership Updates

    View All

    Dexcom Announces Governance Enhancements Ahead of 2026 Investor Day

    Will Add Two Independent Directors with MedTech and Operations Experience to be Named at a Later Date Reconstituted Operations and Innovation Committee Will Expand Mandate to Oversee Operations, Quality and Technical Roadmap Initiatives Follow Constructive Engagement with Elliott Management DexCom, Inc. (NASDAQ:DXCM) today announced key updates to its governance structure in conjunction with its upcoming 2026 Investor Day presentation that outlines a strategic and financial vision to best position the company for future growth. "We look forward to articulating our exciting vision for growth later today at Investor Day as we seek to empower greater metabolic health through our biosen

    5/14/26 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Appoints Rick Osterloh to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Rick Osterloh to its Board of Directors, effective February 26, 2026. Mr. Osterloh is a highly accomplished technology executive with more than 20 years of leadership experience across consumer hardware, platform strategy and large-scale product operations. He currently serves as Senior Vice President, Platforms & Devices at Google, where he leads a unified group spanning the company's portfolio of advanced consumer technologies. This includes Android, Google Play, Chrome, and Google's Devices and Services Portfolio—Pixel phones, Google Nest smart home devices, and Fitbit wearables. Und

    2/26/26 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Appoints Euan Ashley to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of Medicine at Stanford University, overseeing Stanford's largest department with 15 divisions and over 800 faculty. Dr. Ashley's research extends across precision medicine, data science, artificial intelligence, and digital health. He has also co-founded seven biotechnology companies and serves as the co-directo

    10/27/25 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care